Activity Overview
This educational activity is an archive of the live presentation held on May 31, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists,
advanced practice professionals, pathologists, oncology nurses, and other
health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Select among available next-generation endocrine monotherapies and combination strategies for patients with ESR1-mutant, HR+/HER2– advanced breast cancer after CDK4/6 inhibitor progression based on clinical trial data, mutation profile, and patient-specific factors
- Evaluate the rationale and emerging evidence for positioning next-generation endocrine agents in the frontline metastatic setting for HR+/HER2– advanced breast cancer
- Interpret emerging clinical trial data for oral SERDs and PROTACs in early-stage, HR+/HER2– breast cancer to identify patients who may benefit from adjuvant or neoadjuvant next-generation endocrine strategies
Ruta D. Rao, MD
Professor of Medicine
Director, Coleman Foundation Comprehensive Breast Cancer Clinic
Medical Director, RUSH University Cancer Center
Chicago, IL
Disclosures: Consultant/Advisor: DSI, Genentech, Lilly, Pfizer, TerSera
Kamel Abou Hussein, MD
Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca; Speakers Bureau: Lilly, Stemline/Menarini
Jame Abraham MD, FACP
Enterprise Chairman, Department of Hematology and Medical Oncology
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH
Disclosures: Advisory Board: OpenEvidence, ThinkBioAI
Paolo Tarantino, MD, PhD
Clinical Fellow Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, MenariniStemline, Novartis, Roche; Grant/Research Funding: AstraZeneca
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
